Valuation: Tengion, Inc.

Market Cap 1L 95.01T 88.81T 81.17T 2L 1.05Cr 2L 10.41L 4L 52.37L 4L 4L 1.74Cr P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 55.52L 48.06L 44.92L 41.06L 77.37L 53Cr 78.58L 5.27Cr 2.07Cr 26Cr 2.08Cr 2.04Cr 88Cr EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%0.00%-39.17%-43.82% 63Cr
+12.54%+8.86%+126.98% - 35Cr
+10.61%+24.73%-28.45%-6.25% 12Cr
-5.51%-9.43%-4.38%+50.94% 9.9Cr
Average +4.01%+1.34%+13.74%+0.29% 30.14Cr
Weighted average by Cap. +3.43%+0.16%+12.93%-27.39%

Financials

2012 2013
Net sales - -
Net income -1.69Cr -1.47Cr -1.37Cr -1.25Cr -2.36Cr -161.46Cr -2.4Cr -16Cr -6.3Cr -81Cr -6.36Cr -6.22Cr -269.02Cr -1.89Cr -1.64Cr -1.53Cr -1.4Cr -2.64Cr -180.51Cr -2.68Cr -18Cr -7.05Cr -90Cr -7.11Cr -6.95Cr -300.77Cr
Net Debt 37.33L 32.32L 30.21L 27.61L 52.02L 36Cr 52.84L 3.54Cr 1.39Cr 18Cr 1.4Cr 1.37Cr 59Cr 54.42L 47.11L 44.04L 40.25L 75.84L 52Cr 77.03L 5.16Cr 2.03Cr 26Cr 2.04Cr 2Cr 86Cr
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
-